慢性複雑性尿路感染症に対するKW-1062とGentamicinの二重盲検法による有効性および安全性の検討

Abstract

In order to examine effectiveness, safety and usefulness of, KW-l062, a new aminoglycoside antibiotic, it was compared with gentamicin (GM) for treatment of chronic complicated urinary tract infection in a double-blind trial. KW-I062 was administered to hospitalized adult patients at the dosage of 120 mg b.i.d. for five days. GM was administered to hospitalized adult patients at the dosage of 60 mg b.i.d. for five days. The number of evaluable cases was 105 for KW-1062 and 95 for GM, and the results obtained were as follows. 1) No significant difference was observed between the KW-1062 group and GM group in various background factors related to the characteristic of patients. 2) KW-l062 showed a significantly higher rate of efficacy on bacteriuria and overall clinical efficacy (p<0.05). 3) Side effects and abnormal laboratory findings occurred at a low frequency in both treatment groups, and there were no significant differences between both groups.